A US Survey Across Seven Early-Stage Cancers Assessing the Humanistic Burden of Recurrence on Patients and Caregivers
Our findings demonstrate the importance of preventing recurrences and their negative impact on patients' and caregivers' QoL. Early-stage cancer treatments that prevent recurrences can provide better QoL.
Authors
- Rutika Raina (ORCID: https://orcid.org/0000-0002-1585-4514)
- Ana Martinez
- Raquel Aguiar‐Ibáñez (ORCID: https://orcid.org/0000-0002-3839-6966)
- Hannah Penton (ORCID: https://orcid.org/0000-0001-9492-7875)
- Marieke Heisen (ORCID: https://orcid.org/0000-0002-5339-6606)
- Kelly McQuarrie (ORCID: https://orcid.org/0000-0002-2362-1163)
- Sayeli Jayade (ORCID: https://orcid.org/0000-0002-3058-9624)
- Laura DiGiovanni (ORCID: https://orcid.org/0000-0002-8654-0117)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Open Society Foundations (US)
- Heritage College (CA)
- Pharmerit (Netherlands) (NL)
- Merck Canada Inc. (Canada) (CA)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1007/s40487-025-00328-4
- Citations
- 4
- Primary Topic
- Cancer survivorship and care
- Type
- article
- Field-Weighted Citation Impact
- 4.18
Funders
- Merck